ASBP (40) LSTA (29) GTBP (36) LPCN (23) ⌘ Pro Terminal →

Cellectar Biosciences Inc. (CLRB) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell CLRB stock right now?

Cellectar Biosciences Inc. (CLRB) currently earns a Roarable Rating of E (Strong Sell — SELL) with 32/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is CLRB's 12-month price target and RQD AI Jury consensus?

CLRB's 12-month base price target is $1.07 (range $0.83 to $4.94), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$1.21 -1.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.21

Cellectar Biosciences Inc. (CLRB) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $11.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLRB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cellectar Biosciences Inc. (NASDAQ: CLRB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.21 (-1.23% 1D, market cap $11.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CLRB ranks #740 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLRB compare to ASBP and LSTA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLRB carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ASBP (Aspire-Lakewood Holdings Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.4M) and LSTA (Lisata Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M). Among the 5-stock peer group, CLRB leads on earnings multiple (N/A) while CLRB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLRB?

▼

Per CLRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001279704), Cellectar Biosciences Inc. generated $0 in revenue, -$21.8M in net income, and -$23.1M in free cash flow against $15.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.21 (-0.41%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLRB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY CLRB SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 30.7 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.39-11.5% Next Q

Q2 (-2Q)

Grade E$1.23-1.6% Next Q

Q3 (-1Q)

Grade E$1.21+0% Next Q

Current

Grade E$1.21-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLRB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLRB currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.83) and Max Pain ($1.27) forces dealer call-delta covering toward $4.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLRB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CLRB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

30.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE3% OF RANGE

L: $1$1.21H: $5

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CLRB

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (27)

8/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like CLRB

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLRB)

✓Walkthrough of CLRB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLRB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.24%▼ DESCENDING CHANNEL

2026-11-03O $1.22H $1.22L $1.21C $1.21VOL 55.3K

RES: $2.12SUP: $0.77SMA50: $1.83SMA200: $2.61

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLRB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLRB Butterfly Map → + Track CLRB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLRB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLRB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLRB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLRB)

Health Care Rank #740 of 1016 ⚔️ ASBP vs CLRB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLRB vs. ASBP, LSTA, GTBP, LPCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cellectar Biosciences Inc. (CLRB) ranks #740 by composite RQD confidence (32/100, grade E) and #881 by equity capitalization ($11.4M). Within this direct 5-issuer industry benchmark cohort, CLRB leads on earnings valuation at N/A trailing P/E, while CLRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ASBP currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with CLRB at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLRB ACTIVE Cellectar Biosciences Inc.	E	32/100	—	—	-35.0%	-1.23%	$11.4M	Benchmark Subject
ASBP Aspire-Lakewood Holdings Inc.	D-	40/100	—	-1.9%	-35.0%	-4.36%	$11.4M	/asbp-vs-clrb →
LSTA Lisata Therapeutics Inc.	E	29/100	—	—	-35.0%	+0.99%	$11.0M	/lsta-vs-clrb →
GTBP GT Biopharma Inc.	D-	36/100	—	—	-35.0%	-5.00%	$11.0M	/gtbp-vs-clrb →
LPCN Lipocine Inc.	E	23/100	—	—	-35.0%	-5.26%	$11.9M	/lpcn-vs-clrb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001279704

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cellectar Biosciences Inc. (CLRB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$21.8M, operating cash flow of -$23.1M, and free cash flow of -$23.1M (+51.5% YoY). On the balance sheet, CLRB closed FY2025 with $15.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$21.8M	-$23.1M	-$23.1M	$15.0M	—
FY2024 (FY)	2024-12-31	$0	-$44.6M	-$47.6M	-$47.7M	$25.5M	—
FY2023 (FY)	2023-12-31	$0	-$38.0M	-$32.4M	-$32.4M	—	—

3. CLRB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CLRB compare to ASBP and LSTA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CLRB?

Where is CLRB trading relative to its 50-day, 200-day, and 52-week technical levels?

CLRB last traded at $1.21 (-1.23% on volume of 55,293 shares), positioning the stock -33.88% below its 50-day simple moving average ($1.83) and -53.64% below its 200-day simple moving average ($2.61). Across its 52-week range of $1.12 to $4.70, CLRB sits at the 2.5% percentile with a 14-day RSI of 30.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.06 to $1.36).

CLRB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CLRB stock right now?

Cellectar Biosciences Inc. (CLRB) currently earns a Roarable Rating of E (Strong Sell — SELL) with 32/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is CLRB's 12-month price target and RQD AI Jury consensus?

CLRB's 12-month base price target is $1.07 (range $0.83 to $4.94), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CLRB RQD Cockpit CLRB 12M Forecast CLRB Earnings & Move CLRB Dividends & DRIP CLRB Insiders & 13F CLRB Whale Options CLRB Profit Sankey CLRB News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CLRB — Cellectar Biosciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:51:27Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CLRB scores 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 6 out of 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating cash returns on capital. Whale 13F Flow scores 3 out of 20 for institutional accumulation and options positioning, the weakest pillar in the set. Insider Conviction scores 5 out of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 8 out of 20 with a Beta of 1.0. Forensic Balance Sheet scores 10 out of 20, reflecting an Altman Z of 2.5, a Piotroski F of 2 out of 9, and a Debt/Equity of 0.5.

For a prospective investor, the upside case rests almost entirely on the clinical narrative in the news wire rather than on current financial performance; the scoring framework gives limited credit to that narrative. The valuation tradeoff is stark: at a market capitalization of $11.5M and a 0% FCF yield, the equity is priced against operating losses reported in the financials rather than against earnings. The institutional and insider pillars both score poorly, meaning the rating does not find evidence of smart-money conviction to offset the forensic concerns.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-23.0M	$-21.8M	N/A	$-23.1M	$13.2M	N/A
FY 2024	$0.0M	$-51.8M	$-44.6M	N/A	$-47.7M	$23.3M	N/A
FY 2023	$0.0M	$-39.0M	$-38.0M	N/A	$-32.4M	N/A	N/A

Per the SEC financials, reported operating and net losses narrowed from FY 2024 to FY 2025, and cash declined from $23.3M to $13.2M over the same span. Gross, operating, and net margins are each listed as 0% in market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z is 2.5 and the Piotroski F is 2 out of 9; the Debt/Equity is 0.5 per the same rating. Debt is reported as N/A in every period, so the source data does not confirm the debt level underlying that ratio.

Open Questions

What is the company's cash runway given FY 2025 cash of $13.2M and FCF of $-23.1M, and does the source data contain a funding plan?
Why does the profile list market capitalization as $0.0B while market data shows $11.5M, and which figure is current?
What are the debt obligations behind the reported Debt/Equity of 0.5, since debt is N/A in every financial period?
Does the Iopofosine I 131 program have regulatory milestones or revenue timing that the source data documents?
Who holds the shares, given that holder and institutional data are unavailable?

CLRB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cellectar Biosciences Inc. (CLRB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLRB Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 17h ago

Cellectar Biosciences, Inc. Estimates – NASDAQ:CLRB

TradingView report covering Cellectar Biosciences Inc. (CLRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 20h ago

Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131

Yahoo Finance report covering Cellectar Biosciences Inc. (CLRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

Cellectar's Nov. 10 call is set for 8:30 a.m. Eastern, with third-quarter results and an update.

Stock Titan report covering Cellectar Biosciences Inc. (CLRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

CLRB Q3'26 Earnings: revenue estimate is 0 USD

TradingView report covering Cellectar Biosciences Inc. (CLRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Cellectar Biosciences (CLRB) Slips 4.30% as Shares Test Lower End of Recent Range - ETF Creation Redemption

https://www.siam.in/ report covering Cellectar Biosciences Inc. (CLRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

One lymphoma patient had no disease progression for over eight years after one treatment.

Stock Titan report covering Cellectar Biosciences Inc. (CLRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

CLRB Q3'26 Earnings: EPS estimate is (0.56) USD

TradingView report covering Cellectar Biosciences Inc. (CLRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Cellectar Biosciences, Inc. (CLRB) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Cellectar Biosciences Inc. (CLRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLRB Bull vs. Bear Conversation Board — What's Your Call at $1.21?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLRB 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.07 (-12.3%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CLRB (E • RQD 32/100) a Buy at $1.22?

Welcome to the CLRB (Cellectar Biosciences Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.93 (-23.8%)

Spot @ $1.22

Pump the brakes on CLRB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CLRB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cellectar Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.49 (+22.1%)

Spot @ $1.22

CLRB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CLRB, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.22 (52-wk range $1.12 - $4.70), any beat on forward guidance forces shorts and underweight funds to chase.